Molecular Dx Labs Fret Over Medicare Payment Setting, Or, In Some Cases, Lack Thereof
This article was originally published in The Gray Sheet
Executive Summary
The industry’s angst is growing several months after CMS announced a plan to task contractors with independently setting regional payments for more than 100 new molecular diagnostic codes. A breakdown in the process so far, stakeholders say, could have a lasting impact on small, venture-backed labs.
You may also be interested in...
Gottlieb Joins HHS Transition Team; Will Next Stop Be FDA?
Former US FDA, CMS official has been among those thought to be in the running for Trump's FDA commissioner nomination.
BRCA Reimbursement Cut Heightens Tensions Between CMS And Lab Industry
CMS has extended the comment period on its nearly 50 percent BRCA testing reimbursement cut to the end of February. But comments from lab and diagnostics groups so far try to underscore the “capriciousness and lack of transparency” that CMS displayed when it made the cut. Experts say the agency is unlikely to change its mind.
Lab Tests Face Revaluation, Cuts Under New CMS Proposals
CMS is proposing a comprehensive review process to ensure test payments account for changes in technology. The effort would likely lead to pay reductions in many instances to address new efficiencies in the lab. In addition, double-digit cuts in lab payments are proposed in the agency’s 2014 physician fee schedule draft.